90 results about "Doxorubicinone" patented technology

Doxorubicin block copolymer formulations for use in preparing injectable compositions for treating cancer patients which contain lactose for solubilizing the doxorubicin and block copolymers in said formulations and methyl paraben for stabilizing these formulations, as well as a method of preparing and using these injectable compositions.

A process for the large scale production of a liposome suspension, in which three selected lipid compounds in a predetermined ratio are dissolved in an alcohol solvent to form a mixture, which, in turn, is directly admixed with an aqueous ammonium sulfate solution in a predetermined ratio. The resultant mixture is subjected to a pore-extrusion treatment, followed by dialyzing the pore-extruded mixture with a 5% to 15% sucrose aqueous solution, such that a liposome suspension containing liposome particles suspended in the liposome suspension is obtained. The thus obtained liposome suspension can be used to encapsulate a selected drug, in particular doxorubicin.

The invention provides a preparation method and application of a temperature and oxidant dual stimuli responsive nano-aggregate. According to the invention, the redox inclusion principle of beta-cyclodextrin (beta-CD) and ferrocene (Fc) and the temperature sensitive properties of the polymer poly(N-isopropylacrylamide) (PNIPAM) are utilized to connect PNIPAM-beta-CD with the end containing a beta-CD host group to hydrophilic polyethylene glycol (mPEG-Fc) with the end modified by an Fc guest group in a water solution through a host-guest recognized noncovalent bond, thus forming a supramolecular complex mPEG-Fc/PNIPAM-beta-CD. When the temperature is higher than the LCST (lower critical solution temperature) of PNIPAM, the macromolecular adduct can further gather in water to form a micellar structure. Micelle formation and disintegration can be realized by adjusting the solution temperature and adding an oxidant. cytotoxicity assessment experiments find that the supramolecular complex has very good biocompatibility. The supramolecular micelle packing the anticancer drug doxorubicin has very good effect in inhibiting A549 tumor cell growth. The preparation method of the nano-aggregate is simple, environment-friendly and economical, and the nano-aggregate has great application value in the field of biological medicine.

The present invention provides methods for preparing a gene expression profile of a breast cancer cell, tumor, or cell line, where the gene expression profile may be evaluated for one or more gene expression signatures indicative of multidrug resistance. The signature may be indicative of resistance to one or more chemotherapeutic agents selected from a Taxol (e.g., Docetaxel or Paclitaxel), an antibiotic (e.g., Doxorubicin or Epirubicin), an antimetabolite (e.g., Fluorouracil and/or Gemcitabine), and an alkylating agent (e.g., Cyclophosphamide). Generally, the gene expression profile contains the level of expression for a plurality of genes listed in FIGS. 3, 4, and/or 5. Gene expression profiles for evaluating multidrug resistance for ER positive and ER negative breast cancers are also provided.

A polymeric drug, in which a cancerostatic connected via spacers containing hydrolytically cleavable hydrazone bonds is bound to a water-soluble polymeric carrier prepared on the basis of a N-(2-hydroxypropyl)methacrylamide copolymer, wherein the structure of the polymeric drug consists of the main chain of N-(2-hydroxypropyl)methacrylamide carrying the cancerostatic and another chain of N-(2-hydroxypropyl)methacrylamide—a graft, which may also carry a cancerostatic, said grafts being bound to the main chain by a bond that is stable in the body and/or by a bond cleavable in the body, especially by an oligopeptide spacer selected from the series of GlyLeuGly, GlyPheGly, GlyPheLeuGly and GlyLeuPheGly, and a method of its preparation.

The invention relates to pH sensitive doxorubicin nanoliposome modified by folic acid-carboxymethyl chitosan and its preparation method. The liposome provided in the invention comprises doxorubicin, phosphatide, cholesterol, vitamin E, folic acid-carboxymethyl chitosan. The prepared liposome has pH sensitivity, tumor targeting performance and long cyclic active targeting drug delivery functions.

The invention discloses a preparation method and application of Fe3O4@CA-beta-CD nano microspheres. By adopting an ultrasonic-assisted coprecipitation method, citric acid modified Fe3O4@CA nanoparticles are synthesized. The preparation method comprises the following steps: adding Fe3O4@CA into distilled water, thereby obtaining a Fe3O4@CA solution; adding beta-cyclodextrin into the Fe3O4@CA solution, uniformly stirring, drying, washing, and separating by using a strong magnet, thereby obtaining the Fe3O4@CA-beta-CD nano microspheres; performing ultrasonic dispersion on Fe3O4@CA-beta-CD nano microspheres in deoxidated distilled water, adding doxorubicin, performing ultrasonic treatment by using an ultrasonic cell cracker, separating, washing, and drying, thereby obtaining doxorubicin-supported ferroferric oxide nano microspheres Fe3O4@CA-beta-CD-DOX. The microspheres are slow-released in a phosphate buffer at the pH value of 7.4, the release time is 12 hours, and a slow release effect is achieved.

The present invention provides for use of an anthracycline, such as doxorubicin, alone or in combination with a protective agent, such as dexrazoxane, for treating multiple sclerosis.

The invention discloses a nonlinear polymer having a doxorubicin structure, and a preparation method and an application thereof. The doxorubicin coupled nonlinear polymer has better effects on treatment of age-related macular degeneration compared with other forms of drugs or medicaments.

The invention discloses a novel antitumor doxorubicin-containing macromolecular drug. A preparation method includes the steps: polymerizing acrylic acid by an atomic transfer radical polymerization method to obtain polyacrylic acid; polymerizing lysine benzyl ester carboxylic acid anhydride by a ring opening polymerization method, to obtain poly(lysine benzyl ester); grafting poly(lysine benzyl ester) with adriamycin through a hydrazone bond; carrying out bond connection of polyacrylic acid and poly(lysine benzyl ester) by a click chemistry method, to obtain a block copolymer; dissolving the block polymer in tetrahydrofuran, transferring into a dialysis bag, dialyzing with pure water, and filtering the dialyzed liquid with a filter membrane; and freeze-drying the filtered solution, and thus obtaining drug-loaded micelles. The drug carrier micelles have a core-shell double-layer structure, an outer layer is hydrophilic polyacrylic acid, and an inner layer is a drug molecular wrapping layer. The material has the following advantages that the material belongs to nanoparticles, can realize targeted delivery of drugs on cancer cells and pH sensitive release in the cancer cells, and has large drug loading capacity and good stability; and the targeted function can effectively reduce toxic and side effects of the drugs to normal tissues and organs.

The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) a chemotherapeutic drug subject to multi-drug resistance by P-gp, such as doxorubicin or an analog thereof. The pharmaceutical composition is useful for treating cancer. The pharmaceutical composition is also useful for i) preventing or treating multi-drug resistance in a subject or ii) preventing a chemotherapeutic drug subject to multi-drug resistance by P-gp induced cardiac tissue damage in a subject, such as doxorubicin or an analog thereof. The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) a chemotherapeutic drug subject to multi-drug resistance by P-gp, such as doxorubicin or an analog thereof. The pharmaceutical composition is useful for treating cancer. The pharmaceutical composition is also useful for i) preventing or treating multiamrg resistance in a subject or ii) preventing a chemotherapeutic drug subject to multi-drug resistance by P-gp induced cardiac tissue damage in a subject, such as doxorubicin or an analog thereof.